|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.88 USD | +0.70% |
|
+1.02% | -40.23% |
| 04-29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
| 04-26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
Teladoc Health, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 646.13 million compared to USD 629.24 million a year ago. Net loss was USD 81.89 million compared to USD 69.23 million a year ago.
Basic loss per share from continuing operations was USD 0.49 compared to USD 0.42 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -40.23% | 2.18B | |
| +115.18% | 703M | |
| +5.91% | 456M | |
| -62.69% | 165M | |
| -45.18% | 70.49M |
TELADOC HEALTH, INC. 
